JBIO Jade Biosciences, Inc.

NASDAQ
$15.34

Jade Biosciences, Inc. (JBIO) is expected to report earnings on February 12, 2027, after the market close. The consensus earnings estimate is a loss of $0.72 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -5.8% since its last earnings release on November 13, 2026.

Jade Biosciences Beat Consensus Estimates
Friday, November 13, 2026 · 7:00 AM ET
Earnings Date
4th Quarter, Dec 2026
Feb 12
Friday · After Close
Earnings Whisper
-
vs ($0.72)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $15.61

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Jade Biosciences, Inc.

Jade Biosciences Inc. is focused on developing therapies to address critical unmet needs in autoimmune diseases. The company pipeline includes antibody discovery programs, JADE-002 and JADE-003, currently in preclinical development. Jade Biosciences Inc., formerly known as Aerovate Therapeutics Inc., is based in WALTHAM, Mass.

Sector

Healthcare

Industry

Biotechnology

Held By 1 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.